Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Vicki J. Adams is active.

Publication


Featured researches published by Vicki J. Adams.


Veterinary Record | 2006

Treatment with gabapentin of 11 dogs with refractory idiopathic epilepsy

Simon R. Platt; Vicki J. Adams; Laurent S. Garosi; C. J. Abramson; J. Penderis; A. De Stefani; Lara Matiasek

Eleven dogs diagnosed with refractory idiopathic epilepsy were treated orally with gabapentin for a minimum of three months at an initial dose of 10 mg/kg every eight hours. They were all experiencing episodes of generalised tonic-clonic seizures and had been treated chronically with a combination of phenobarbital and potassium bromide at doses sufficient to reach acceptable therapeutic serum levels without causing significant side effects. In each dog, the number of seizures per week, the average duration of the seizures and the number of days on which seizures occurred were compared for the three months before and after they were treated with gabapentin. A minimum 50 per cent reduction in the number of seizures per week was interpreted as a positive response to gabapentin, and six of the dogs showed a positive response. After the addition of gabapentin, both the number of seizures per week (P= 0·005) and the number of days with any seizures in a one-week period (P=0·03) were significantly reduced. Mild side effects of ataxia and sedation were observed in five of the dogs, but they were not severe enough to warrant the treatment being discontinued during the trial.


Journal of Comparative Pathology | 2006

COX-1 and COX-2 Expression in Feline Oral Squamous Cell Carcinoma

A. Hayes; T. J. Scase; J. Miller; S. Murphy; Andrew H Sparkes; Vicki J. Adams

This study demonstrated immunohistochemically the expression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in feline oral squamous cell carcinoma (FOSCC), with primary polyclonal antibodies raised against human epitopes. COX-2 immunolabelling was intracytoplasmic and, in some neoplastic cells, perinuclear; it was demonstrated in a small proportion (< or = 1%) of neoplastic cells and its intensity was usually mild to moderate. In contrast, all neoplastic tissues showed extensive nuclear and cytoplasmic COX-1 immunolabelling. Cytoplasmic COX-1 immunolabelling was less intense than nuclear labelling in neoplastic tissue. In the adjacent histologically normal oral mucosa, COX-2 immunolabelling was absent. The cytoplasmic and nuclear intensity and distribution of COX-1 immunolabelling was significantly higher in neoplastic tissue than in adjacent normal oral mucosa. The results indicate that COX-1 and COX-2 are overexpressed in FOSCC, but the clinical and pathophysiological significance of this finding remains to be determined.


Journal of Veterinary Internal Medicine | 2007

Magnetic Resonance Imaging Findings and Clinical Associations in 52 Dogs with Suspected Ischemic Myelopathy

Luisa De Risio; Vicki J. Adams; Ruth Dennis; Fraser McConnell; Simon R. Platt

BACKGROUND The magnetic resonance imaging (MRI) features of ischemic myelopathy have been described in the human literature and in a small number of cases in the veterinary literature. HYPOTHESIS The aims of this study were to identify associations among MRI findings, timing of imaging, and presenting neurologic deficits in a large series of dogs with a presumptive diagnosis of ischemic myelopathy. ANIMALS AND METHODS The medical records and MR images of dogs with a presumptive diagnosis of ischemic myelopathy (2000-2006) were reviewed retrospectively. Inclusion criteria were acute onset of nonprogressive and nonpainful myelopathy, 1.5-tesla MRI of the spine performed within 7 days of onset, and complete medical records and follow-up information. Presumptive diagnosis was based on history, as well as clinical, MRI, and cerebrospinal fluid (CSF) findings. The extent of the lesion on MRI was assessed as the following: (1) the ratio between the length of the hyperintense area on sagittal T2-weighted images and the length of C6 or L2 vertebral body, and (2) the maximal cross-sectional area of the hyperintense area on transverse T2-weighted images as a percentage of cross-sectional area of the spinal cord. RESULTS Fifty-two dogs met the inclusion criteria. MRI findings were abnormal in 41 dogs and normal in 11 dogs. The presence of MRI abnormalities was not significantly associated with the timing of imaging (P = .3) but was associated with ambulatory status on presentation (P = .04). Severity of signs on presentation was associated with extent of the lesion on MRI (P = .02). CONCLUSION AND CLINICAL IMPORTANCE The severity of signs on presentation is associated with the presence and the extent of the lesion on MRI.


Veterinary and Comparative Oncology | 2008

Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours.

G. Maglennon; S. Murphy; Vicki J. Adams; J. Miller; K. C. Smith; A. S. Blunden; T. J. Scase

Intermediate-grade mast cell tumours (MCT) represent a heterogeneous population of tumours. The prognosis for the majority of dogs is excellent following surgical excision, but a minority die because of their disease. A previous study identified Ki67 expression as a predictor of prognosis in all three grades of MCT. The purpose of this study was to validate those results in a new group of dogs, with intermediate-grade MCT only. Ki67 immunohistochemistry was performed on intermediate-grade MCT from 163 dogs with known outcome. Digital microscopy images were taken from each tumour, and an index calculated of Ki67-positive cells. Ki67 index as a binary variable with a cut-off value of 1.8% was confirmed to be associated with prognosis (hazard ratio = 19.1, P < 0.0001) for this cohort of dogs. The 1-year, 2-year and 3-year survival probabilities (with standard errors) of 127 dogs with a Ki67 index <or=1.8% were [0.95 (0.024), similar for all] and for 36 dogs with a Ki67 index >1.8% were 0.54 (0.100), 0.45 (0.101) and 0.33 (0.104), respectively.


Journal of Small Animal Practice | 2010

Proportion of litters of purebred dogs born by caesarean section

Katy M. Evans; Vicki J. Adams

OBJECTIVES To describe the frequency of caesarean sections in a large sample of pedigree dogs in the UK. METHODS Data on the numbers of litters born in the previous 10 years were available from a cross-sectional study of dogs belonging to breed club members (2004 Kennel Club/BSAVA Scientific Committee Purebred Dog Health Survey). In this survey 151 breeds were represented with data for households that had reported on at least 10 litters (range 10-14,15): this represented 13,141 bitches which had whelped 22,005 litters. The frequency of caesarean sections was estimated as the percentage of litters that were reported to be born by caesarean section (caesarean rates) and are reported by breed. The dogs were categorised into brachycephalic, mesocephalic and dolicocephalic breeds. RESULTS The 10 breeds with the highest caesarean rates were the Boston terrier, bulldog, French bulldog, mastiff, Scottish terrier, miniature bull terrier, German wirehaired pointer, Clumber spaniel, Pekingese and Dandie Dinmont terrier. In the Boston terrier, bulldog and French bulldog, the rate was > 80%. CLINICAL SIGNIFICANCE These data provide evidence for the need to monitor caesarean rates in certain breeds of dog.


Journal of Small Animal Practice | 2010

Mortality and morbidity due to gastric dilatation-volvulus syndrome in pedigree dogs in the UK

Katy M. Evans; Vicki J. Adams

OBJECTIVES To estimate breed-specific risk of death due to, and prevalence of, gastric dilatation-volvulus (GDV) in UK pedigree dogs. METHODS Data were available on the reported cause of and age at death and occurrence of and age at diagnosis of disease from the 2004 purebred dog health survey. A total of 15,881 dogs of 165 breeds had died in the previous 10 years; GDV was the cause of death in 65 breeds. There were 36,006 live dogs of 169 breeds of which 48 breeds had experienced > or =1 episodes of GDV. Prevalence ratios were used to estimate breed-specific GDV mortality and morbidity risks. RESULTS Gastric dilatation-volvulus was the cause of death for 389 dogs, representing 2.5% (95% CI: 2.2-2.7) of all deaths reported and the median age at death was 7.92 years. There were 253 episodes in 238 live dogs. The median age at first diagnosis was five years. Breeds at greatest risk of GDV mortality were the bloodhound, Grand Bleu de Gascogne, German longhaired pointer and Neapolitan mastiff. Breeds at greatest risk of GDV morbidity were the Grand Bleu de Gascogne, bloodhound, otterhound, Irish setter and Weimaraner. CLINICAL SIGNIFICANCE These results suggest that 16 breeds, mainly large/giant, are at increased risk of morbidity/mortality due to GDV.


Veterinary and Comparative Oncology | 2007

Vinblastine and prednisolone chemotherapy for surgically excised grade III canine cutaneous mast cell tumours

A. Hayes; Vicki J. Adams; Ken C. Smith; G. Maglennon; S. Murphy

The effect of treatment with vinblastine and prednisolone chemotherapy in dogs undergoing only surgical excision of Patnaik grade III cutaneous mast cell tumours is reported. Potential explanatory variables were explored using Kaplan-Meier survival analysis with log-rank tests. During a median follow-up period of 429 days, the overall median survival time (MST) was not reached (lower 95% CI = 322 days). The 1-year survival probability was 0.71 (standard error 0.1), remaining unchanged at 2 years. Secondary disease at presentation was an independent risk factor for survival (P = 0.045). The MST of dogs presenting with secondary disease was 322 days, with a lower 95% confidence interval of 142 days and a 1-year survival of probability of 0.47 (standard error 0.19). Adverse effects were recorded in 6 of the 108 (5.6%) vinblastine doses given. This chemotherapy regimen is a well-tolerated adjunct to surgery for grade III mast cell tumours and appears to prolong survival compared with that expected with surgery alone.


Journal of Veterinary Internal Medicine | 2009

Ki-67 and vascular endothelial growth factor expression in intracranial meningiomas in dogs.

Lara Matiasek; Simon R. Platt; Vicki J. Adams; Timothy J. Scase; D. Keys; J. Miller; Filippo P. Adamo; S. Long; Kaspar Matiasek

BACKGROUND Tumor proliferation in human intracranial meningiomas can be defined by the reactivity of the monoclonal antibody MIB-1 to the Ki-67 antigen. Vascular endothelial growth factor (VEGF), a pro-angiogenic factor, is a predictive marker for survival of dogs with intracranial meningiomas. HYPOTHESIS Ki-67 is expressed in canine intracranial meningiomas and is associated with VEGF expression. Ki-67 expression is a prognostic marker for patient outcome. ANIMALS Seventy client-owned dogs with WHO grade I intracranial meningiomas. METHODS Retrospective study assessing the degree of immunostaining for Ki-67 by MIB-1 and VEGF expression in intracranial meningioma tissue from dogs. MIB-1 Labeling Index (LI) was calculated with Image J NIH-software. Extent, intensity, and distribution of VEGF-expression was assessed semiquantitatively. Cross tabulations with Fishers exact tests and nonparametric Spearmans rank correlations were performed to identify associations between VEGF expression and MIB-1 LI. Fifteen dogs underwent postsurgical radiotherapy and were included in survival analysis. The effect of MIB-1 LI on survival was examined by Kaplan-Meier and Cox proportional hazards regression procedures. RESULTS Ki-67 staining was positive in 91% (64/70) and VEGF expression was detected in 96% (67/70). There was no significant association between VEGF expression and MIB-1 LI. MIB-1 LI was not associated with survival. CONCLUSIONS AND CLINICAL IMPORTANCE MIB-1 antibody can be used to document cell proliferation in intracranial meningiomas in dogs, but does not predict outcome. No association between VEGF as a marker of angiogenesis and tumor proliferation was found. Angiogenesis might be a more important predictor of meningioma activity in dogs than is Ki-67.


Journal of The American Animal Hospital Association | 2009

Evaluations of Labrador retrievers with exercise-induced collapse, including response to a standardized strenuous exercise protocol.

Susan M. Taylor; Cindy L. Shmon; Vicki J. Adams; James R. Mickelson; Edward E. Patterson; G. Diane Shelton

Clinical and metabolic variables were evaluated in 14 Labrador retrievers with exercise-induced collapse (EIC) before, during, and following completion of a standardized strenuous exercise protocol. Findings were compared with previously reported variables from 14 normal Labrador retrievers that participated in the same protocol. Ten of 14 dogs with EIC developed an abnormal gait during evaluation, and these dogs were significantly more tachycardic and had a more severe respiratory alkalosis after exercise compared to the normal dogs. Muscle biopsy characteristics and sequential lactate and pyruvate concentrations were normal. Genetic testing and linkage analysis excluded malignant hyperthermia as the cause of EIC. Common causes of exercise intolerance were eliminated, but the cause of collapse in EIC was not determined.


Journal of Feline Medicine and Surgery | 2009

Clinical and magnetic resonance imaging findings in 92 cats with clinical signs of spinal cord disease

Rita Gonçalves; Simon R. Platt; Francisco J. Llabrés-Díaz; K. Rogers; Alberta de Stefani; Lara Matiasek; Vicki J. Adams

Medical records of 92 cats presented with clinical signs of spinal cord disease, which had undergone magnetic resonance imaging (MRI), were reviewed. The cats were grouped into seven categories based upon the diagnosis suggested by results of MRI, cerebrospinal fluid analysis and other diagnostic procedures: neoplastic (n=25), inflammatory or infectious (n=13), traumatic (n=8), vascular (n=6), degenerative (n=5), anomalous (n=3) and those with an unremarkable MRI (n=32). There were two independent predictors of abnormal MRI findings: severity of clinical signs and presence of spinal pain. Abnormal MRI findings and speed of onset of disease were significantly associated with survival. For the 32 cats with unremarkable MRI findings, only nine died due to spinal disease and, therefore, the median survival time (MST) was not reached (lower 95% confidence interval (CI)=970 days). For the 60 cats with abnormal MRI findings, 37 died due to their disease and the MST was 138 days (95% CI: 7–807).

Collaboration


Dive into the Vicki J. Adams's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge